CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Screening of a pooled library of chimeric antigen receptor T cells based on secretory function.
Screening of a pooled library of chimeric antigen receptor T cells based on secretory function.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞疗法在治疗血液系统恶性肿瘤方面已显示出前景,但由于免疫抑制、抗原异质性和功能筛选平台不足,挑战依然存在。
在此,我们提出了一种基于模块化纳米瓶(nanovial)的平台,用于对混合CAR-T 细胞文库进行高通量、单细胞功能筛选。纳米瓶是一种具有纳升级空腔的水凝胶微粒,通过重组HER2抗原和细胞因子捕获抗体进行功能化修饰,以模拟抗原呈递细胞并捕获分泌的干扰素-(IFN)。该系统能够基于抗原结合和细胞因子分泌,对CAR-T 细胞进行选择性捕获、激活和功能分析。
我们筛选了一个包含32种变体的CAR文库,这些变体具有不同的细胞内信号传导结构域,利用纳米瓶在3小时和12小时时间点分离分泌IFN的细胞。含有IL15RA的CAR,尤其是IL15RA-CD28,在刺激3小时后优先富集于分选出的T细胞中,这与早期效应激活特征一致。到12小时时,含有IL15RA的构建体仍保持富集,而其他含有CD40的结构域则显示出延迟但显著的富集,提示信号传导动态持续时间较长。该平台的高通量能力(筛选超过200万个细胞)、与下游测序的兼容性以及可调节的抗原呈递特性,使其非常适合鉴定与各种时间依赖性分泌表型相关的CAR构建体。
Chimeric antigen receptor (CAR) T cell therapies have shown promise in treating hematologic malignancies, but challenges remain due to immune suppression, antigen heterogeneity, and insufficient functional screening platforms.
Here, we present a modular nanovial-based platform for high-throughput, single-cell functional screening of pooled CAR T cell libraries. Nanovials, hydrogel microparticles with nanoliter-scale cavities, were functionalized with recombinant HER2 antigen and cytokine-capture antibodies to simulate antigen-presenting cells and capture secreted interferon- (IFN ). This system enabled the selective capture, activation, and functional profiling of CAR T cells based on antigen engagement and cytokine secretion.
We screened a 32-variant CAR library with diverse intracellular signaling domains, using nanovials to isolate IFN -secreting cells at 3- and 12-hour timepoints. IL15RA-containing CARs, particularly IL15RA-CD28, were preferentially enriched in the sorted T cells after 3 hours of stimulation, consistent with early effector activation profiles.
By 12 hours, IL15RA-containing constructs remained enriched while other CD40-containing domains showed delayed but substantial enrichment, suggesting prolonged signaling dynamics. The platform's high-throughput capacity (>2 million cells screened), compatibility with downstream sequencing, and tunable antigen presentation make it ideal of identifying CAR constructs associated with various time-dependent secretion phenotypes.
MEMBER ACCOUNT
登录成功会直接打开下一页。